WhiteOak Capital ELSS Tax Saver Fund
The scheme seeks to generate capital appreciation / income from a portfolio, comprising predominantly of equity & equity related instruments.
Growthvine rating: 5/5 — ranked #3 of 57 in category.
Fund basics
| Category | Equity: ELSS |
|---|
| NAV | ₹16.80 (as of 2026-10-23) |
|---|
| AUM | ₹507 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ramesh Mantri |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Sharpe ratio | 0.53 |
|---|
| Standard deviation | 15.43% |
|---|
| Max drawdown | −16.66% |
|---|
| Alpha | 3.98 |
|---|
| Beta | 0.94 |
|---|
Over 5 years, captured 105.3% of Nifty 500's upside and 87.7% of its downside.
Market cap allocation
| Large cap | 53.7% |
|---|
| Mid cap | 12.0% |
|---|
| Small cap | 34.3% |
|---|
Concentration
| Top 5 holdings | 22.4% |
|---|
| Top 10 holdings | 34.0% |
|---|
| Total holdings | 141 |
|---|
| Index overlap | 40.3% |
|---|
| Active share | 59.7% |
|---|
Top holdings
- ICICI Bank Ltd. — 8.1%
- HDFC Bank Ltd. — 4.0%
- Bharti Airtel Ltd. — 3.9%
- Nestle India Ltd. — 3.5%
- Eternal Limited — 2.8%
- Clearing Corporation of India Ltd — 2.7%
- Kotak Mahindra Bank Ltd. — 2.6%
- State Bank Of India — 2.5%
- Mahindra & Mahindra Ltd. — 2.4%
- Reliance Industries Ltd — 2.3%
Top sectors
- Banking & Financial — 22.6%
- Finance & Investments — 7.6%
- Pharma & Biotech — 6.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −5.2% | Q2 | #14 of 52 |
| 2025 | 3.2% | Q3 | #28 of 51 |
| 2024 | 28.2% | Q1 (Top) | #6 of 51 |
| 2023 | 32.2% | Q2 | #16 of 48 |